Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Disc Medicine, Inc. filings on SEC EDGAR ↗
Disc Medicine closed an underwritten public offering of 6,000,000 shares of common stock at a price of $75.00 per share, generating gross proceeds of $450 million. The company expects the net proceeds to extend its cash runway into 2030, supporting the clinical development and potential commercialization of its hematologic disease treatments, including bitopertin.
Disc Medicine announced positive topline results from its pivotal Phase 3 APOLLO trial of bitopertin in patients with erythropoietic protoporphyria (EPP). The trial met all primary and secondary endpoints, including a 41.4% reduction in whole-blood PPIX and a significant increase in pain-free light tolerance, with an NDA resubmission planned by the end of 2026.
Term
6 months
“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”
John Quisel, J.D., Ph.D., President and Chief Executive Officer
“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”